Maze Therapeutics (NASDAQ:MAZE) CMO Harold Bernstein Sells 16,142 Shares of Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) CMO Harold Bernstein sold 16,142 shares of the firm’s stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $27.61, for a total value of $445,680.62. Following the transaction, the chief marketing officer owned 16,142 shares in the company, valued at approximately $445,680.62. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Harold Bernstein also recently made the following trade(s):

• On Wednesday, July 1st, Harold Bernstein sold 14,609 shares of Maze Therapeutics stock. The stock was sold at an average price of $29.90, for a total transaction of $436,809.10.

Maze Therapeutics Stock Down 1.8%

Shares of MAZE stock traded down $0.49 on Friday, hitting $27.18. The stock had a trading volume of 230,651 shares, compared to its average volume of 663,051. The company has a debt-to-equity ratio of 0.11, a current ratio of 17.88 and a quick ratio of 17.88. The business has a 50 day moving average of $27.73 and a 200 day moving average of $33.08. Maze Therapeutics, Inc. has a 12-month low of $12.81 and a 12-month high of $53.65. The stock has a market cap of $1.51 billion, a price-to-earnings ratio of -10.79 and a beta of 2.21.

Maze Therapeutics (NASDAQ:MAZE) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share for the quarter, hitting the consensus estimate of ($0.76). As a group, analysts expect that Maze Therapeutics, Inc. will post -2.73 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Mass General Brigham Inc purchased a new stake in Maze Therapeutics in the fourth quarter worth $9,943,000. Boothbay Fund Management LLC grew its stake in shares of Maze Therapeutics by 16.3% during the 4th quarter. Boothbay Fund Management LLC now owns 409,372 shares of the company’s stock worth $16,960,000 after acquiring an additional 57,497 shares during the period. Spruce Street Capital LP bought a new position in shares of Maze Therapeutics during the 1st quarter worth $5,970,000. Eventide Asset Management LLC purchased a new stake in Maze Therapeutics in the 4th quarter worth about $13,425,000. Finally, Exome Asset Management LLC bought a new stake in Maze Therapeutics in the 1st quarter valued at about $2,642,000.

Analyst Ratings Changes

MAZE has been the subject of several recent analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Maze Therapeutics in a report on Wednesday, June 24th. BTIG Research reissued a “buy” rating and issued a $46.00 price objective on shares of Maze Therapeutics in a research report on Wednesday. Finally, Wall Street Zen upgraded Maze Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. Two investment analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Maze Therapeutics has a consensus rating of “Buy” and a consensus price target of $66.00.

More Maze Therapeutics News

Here are the key news stories impacting Maze Therapeutics this week:

• Positive Sentiment: BTIG issued a Buy rating. The endorsement adds to the constructive analyst view of Maze’s pipeline and could support investor confidence. Maze Therapeutics Earns Buy Rating from BTIG Research
• Positive Sentiment: Maze strengthened its board with two experienced executives. Paula Johnson, M.D., M.P.H., and Sophie Kornowski, Pharm.D., M.B.A., bring extensive clinical, pharmaceutical, partnering, and commercialization expertise. Management also highlighted additional MZE829 data in late 2026 or early 2027, initial MZE782 data in 2027, and additional trial starts next year. Maze Therapeutics Announces Appointments to Its Board of Directors
• Positive Sentiment: HC Wainwright raised all of its reported EPS forecasts. Estimates improved for third-quarter 2026, fourth-quarter 2026, and fiscal years 2026 through 2030. For example, FY2026 EPS was revised to a loss of $2.81 from $2.96, while FY2030 was revised to a loss of $0.72 from $0.74, indicating expectations for a somewhat faster reduction in losses over time.
• Neutral Sentiment: Maze reported second-quarter 2026 financial results and recent business highlights. The available report headline does not provide the detailed financial figures, so the earnings release’s impact cannot be fully assessed from the supplied information. Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
• Negative Sentiment: Maze remains unprofitable. HC Wainwright’s revised forecasts still call for substantial losses through 2030, and its FY2026 estimate of a $2.81 loss is slightly worse than the $2.73 consensus forecast.
• Negative Sentiment: Reported insider activity is a concern. Company insiders have recorded sales but no purchases during the past six months, potentially weighing on sentiment.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical?stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de?risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.